Atul Humar Selected Research

Ganciclovir (Cytovene)

1/2015	Increased osteoprotegerin predicts poor virological outcome during anticytomegalovirus therapy in solid organ transplant recipients.
6/2013	Human cytomegalovirus infection in humanized liver chimeric mice.
5/2012	Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy.
9/2010	An international survey of cytomegalovirus management practices in lung transplantation.
10/2009	Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease.
3/2006	A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
10/2005	Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease.
6/2005	Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
6/2005	A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
12/2004	Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atul Humar Research Topics

Disease

51	Infections 04/2022 - 06/2001
16	Viremia 01/2020 - 04/2004
11	Human Influenza (Influenza) 01/2021 - 08/2010
8	Cryptococcosis 11/2010 - 10/2005
7	COVID-19 04/2022 - 07/2020
6	Fungemia 11/2010 - 10/2005
5	Pneumonia (Pneumonitis) 01/2020 - 06/2001
4	Cytomegalovirus Infections (Inclusion Disease) 01/2020 - 10/2005
4	Communicable Diseases (Infectious Diseases) 01/2019 - 04/2010
4	Inflammation (Inflammations) 06/2015 - 11/2012
3	Aspergillosis 01/2021 - 01/2015
3	Renal Insufficiency (Renal Failure) 09/2010 - 03/2007
3	Severe Acute Respiratory Syndrome 08/2007 - 08/2003
2	Herpes Zoster 10/2021 - 01/2008
2	Surgical Wound Infection 01/2021 - 01/2018
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2020 - 03/2006
2	Reinfection 01/2020 - 03/2016
2	Hepatitis C 01/2020 - 05/2002
2	Diabetes Mellitus 01/2020 - 01/2018
2	Death (Near-Death Experience) 01/2020 - 09/2017
2	Invasive Fungal Infections 01/2018 - 01/2015
2	Late Onset Disorders 11/2010 - 01/2010
2	Pneumococcal Infections 12/2007 - 05/2003
2	Neutropenia 06/2005 - 04/2004
2	Cystic Fibrosis (Mucoviscidosis) 12/2004 - 06/2001
1	Breakthrough Infections 01/2022
1	Sclerosing Cholangitis 01/2022
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2022
1	Thrombocytopenia (Thrombopenia) 12/2021
1	Thrombosis (Thrombus) 12/2021
1	Asymptomatic Infections 10/2021
1	Chickenpox 10/2021
1	Staphylococcal Infections 01/2021
1	Bacteremia 01/2021
1	Invasive Pulmonary Aspergillosis 12/2020
1	Colitis 01/2020
1	Liver Diseases (Liver Disease) 01/2020
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020
1	Sepsis (Septicemia) 01/2020
1	Coinfection 01/2020
1	Acute Liver Failure (Fulminant Hepatic Failure) 11/2019
1	Dengue (Dengue Fever) 11/2019

Drug/Important Bio-Agent (IBA)

14	VaccinesIBA 04/2022 - 03/2011
12	Antiviral Agents (Antivirals)IBA 01/2020 - 10/2005
11	Ganciclovir (Cytovene)FDA LinkGeneric 01/2015 - 04/2004
10	Valganciclovir FDA Link 01/2017 - 04/2004
5	AntigensIBA 01/2021 - 01/2008
4	Calcineurin InhibitorsIBA 01/2021 - 03/2007
3	Monoclonal AntibodiesIBA 04/2022 - 03/2016
3	CytokinesIBA 01/2020 - 01/2019
3	Pharmaceutical PreparationsIBA 01/2020 - 01/2019
3	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020 - 03/2007
3	Anti-Bacterial Agents (Antibiotics)IBA 11/2014 - 06/2001
3	DNA (Deoxyribonucleic Acid)IBA 06/2013 - 02/2002
2	Oxygen (Dioxygen)IBA 04/2022 - 10/2021
2	Messenger RNA (mRNA)IBA 01/2022 - 12/2021
2	Sirolimus (Rapamycin)FDA Link 01/2022 - 12/2021
2	Tacrolimus (Prograf)FDA LinkGeneric 12/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2004
2	galactomannanIBA 01/2021 - 01/2018
2	Hemagglutinins (Hemagglutinin)IBA 01/2021 - 01/2019
2	Interleukin-10 (Interleukin 10)IBA 01/2019 - 01/2019
2	InterleukinsIBA 01/2019 - 09/2014
2	Interleukin-4 (Interleukin 4)IBA 01/2019 - 12/2014
2	HLA-DR Antigens (HLA-DR)IBA 01/2019 - 12/2014
2	Levofloxacin (Levaquin)FDA Link 11/2014 - 06/2013
2	QuinolonesIBA 11/2014 - 06/2013
2	EnzymesIBA 01/2013 - 11/2012
2	Amphotericin B (Amphotericin)FDA LinkGeneric 12/2009 - 10/2005
2	Antifungal AgentsIBA 02/2008 - 10/2005
2	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 12/2007 - 05/2003
1	sotrovimabIBA 04/2022
1	mRNA VaccinesIBA 04/2022
1	BNT162 VaccineIBA 01/2022
1	Peptides (Polypeptides)IBA 12/2021
1	Prednisone (Sone)FDA LinkGeneric 12/2021
1	Herpes Zoster VaccineIBA 10/2021
1	2019-nCoV Vaccine mRNA-1273IBA 01/2021
1	Immunoglobulin A (IgA)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	letermovirIBA 01/2020
1	glecaprevir and pibrentasvirIBA 01/2020
1	terminaseIBA 01/2020
1	Rituximab (Mabthera)FDA Link 01/2020
1	Ezetimibe (Zetia)FDA Link 01/2020
1	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020

Therapy/Procedure

21	Therapeutics 04/2022 - 06/2005
19	Transplantation 01/2022 - 08/2005
14	Liver Transplantation 01/2022 - 02/2002
11	Lung Transplantation 01/2020 - 12/2004
8	Organ Transplantation 07/2020 - 10/2005
3	Length of Stay 01/2021 - 10/2014
2	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2015
2	Artificial Respiration (Mechanical Ventilation) 10/2021 - 05/2003
2	Drug Therapy (Chemotherapy) 01/2018 - 01/2015
2	Aftercare (After-Treatment) 01/2017 - 06/2005
2	Kidney Transplantation 11/2014 - 06/2013
1	Subcutaneous Injections 01/2021
1	Salvage Therapy 01/2020